4.7 Article

Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS

Journal

NEUROLOGY
Volume 77, Issue 2, Pages 138-144

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318212a901

Keywords

-

Funding

  1. Buffalo Neuroimaging Analysis Center
  2. Baird MS Center
  3. Jacobs Neurological Institute
  4. University of Buffalo
  5. Direct MS Foundation
  6. Jacquemin Family Foundation
  7. Millenium Pharmaceuticals, Inc.
  8. Klein Buendel, Inc.
  9. Alexion Pharmaceuticals, Inc.
  10. Androclus Therapeutics, Inc.
  11. University of Illinois
  12. Amgen
  13. New York University
  14. Somnus Therapeutics, Inc.
  15. ApopLogic Pharmaceuticals
  16. LLC
  17. NIH [NINDS 5U01NS042685-02 [PI], 3R01DC004689-08S1, R01 NS062820-01A2]
  18. NINDS [U01 NS45719-01A1]
  19. NIAID [HHSN266200400068C, N01AI30025, P30AI27767]
  20. NHLBI [5R01 HL06991-02, 5P50HL084923-030001]
  21. NIDR [3R01DE016684-03S109]
  22. NIDDK [1R01DK078826, 1P30DK079337]
  23. Consortium of Multiple Sclerosis Centers (Director NARCOMS Data Center)
  24. National Multiple Sclerosis Society
  25. EMD Serono, Inc.
  26. Novartis
  27. Pfizer Inc.
  28. Biogen Idec
  29. US Department of Defense
  30. Shire plc
  31. Jog for the Jake
  32. Children's Guild Foundation
  33. National MS Society
  34. Teva Pharmaceutical Industries Ltd.
  35. Cyberonics, Inc.

Ask authors/readers for more resources

Background: Chronic cerebrospinal venous insufficiency (CCSVI) was recently described in patients with multiple sclerosis (MS). A subject is considered CCSVI positive if >= 2 venous hemodynamic (VH) criteria are fulfilled. Objective: To determine prevalence of CCSVI in a large cohort of patients with MS, clinically isolated syndrome (CIS), other neurologic diseases (OND), and healthy controls (HC), using specific proposed echo-color Doppler (ECD) criteria. Methods: Transcranial and extracranial ECD were carried out in 499 enrolled subjects (289 MS, 163 HC, 26 OND, 21 CIS). Prevalence rates for CCSVI were calculated in 3 ways: first, using only the subjects for whom diagnosis was certain (i.e., borderline subjects were excluded); secondly, including the borderline subjects in the no CCSVI group; and finally, taking into account subjects who presented any of the VH criteria. Results: CCSVI prevalence with borderline cases included in the no CCSVI group was 56.1% in MS, 42.3% in OND, 38.1% in CIS, and 22.7% in HC (p < 0.001). The CCSVI prevalence figures were 62.5% for MS, 45.8% for OND, 42.1% for CIS, and 25.5% for HC when borderline cases were excluded (p < 0.001). The prevalence of one or more positive VH criteria was the highest in MS (81.3%), followed by CIS (76.2%), OND (65.4%), and HC (55.2%) (p < 0.001). CCSVI prevalence was higher in patients with progressive than in nonprogressive MS (p = 0.004). Conclusions: Our findings are consistent with an increased prevalence of CCSVI in MS but with modest sensitivity/specificity. Our findings point against CCSVI having a primary causative role in the development of MS. Neurology(R) 2011;77:138-144

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available